
|Articles|March 25, 2020
Q2 Solutions Collaborates with University of Texas Medical Branch to Accelerate COVID-19 Vaccines
Advertisement
Q2 Solutions, a clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, announced its collaboration with the University of Texas Medical Branch to develop a novel assay for COVID-19 tests. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Is Artificial Intelligence Coming for Clinical Research?
2
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
3
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
4
The CRA Role’s Co-evolution With Clinical Trial Technology
5






.png)



.png)



.png)
.png)
